Drug profile · INN
ensitrelvir fumaric acid
XOCOVA (NOTE 3)
ensitrelvir fumaric acid (XOCOVA (NOTE 3)) is an FDA-listed pharmaceutical active ingredient.
Drug details — ensitrelvir fumaric acid
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.78
Quick answer
ensitrelvir fumaric acid (XOCOVA (NOTE 3)) is an FDA-listed pharmaceutical active ingredient.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| PMDA | approved | — |
Recent coverage
FDA Approves Ensitrelvir (XOCOVA) as First Oral Option for COVID-19 Post-Exposure Prophylaxis
The FDA has approved Shionogi's ensitrelvir (XOCOVA) as the first and only oral antiviral for post-exposure prophylaxis of COVID-19. This approval addresses a critical prevention gap and introduces a convenient five-day oral regimen.
FDA Approves First Oral COVID-19 PEP Drug, Xocova
The FDA has approved Shionogi's Xocova (ensitrelvir) as the first oral post-exposure prophylaxis (PEP) for COVID-19 in adults and adolescents aged 12 years and older. The approval is based on the Phase 3 SCORPIO-PEP trial.
FDA Approves Xocova: A Catalyst for Pharmaceutical M&A and Licensing
The FDA has approved Shionogi's Xocova, marking a significant development in COVID-19 prevention. This approval coincides with a surge in pharmaceutical industry mergers and licensing deals, signaling a dynamic period for the sector.
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19
Structured plan for FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19
Frequently asked questions
What is ensitrelvir fumaric acid?
ensitrelvir fumaric acid (XOCOVA (NOTE 3)) is an FDA-listed pharmaceutical active ingredient.
What is the brand name for ensitrelvir fumaric acid?
XOCOVA (NOTE 3) is a marketed brand name for ensitrelvir fumaric acid. Check FDA Drugs@FDA for the current US label holder and prescribing information.